Merck & Co., Inc. (FRA:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 214.73B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 13.24 |
| Forward PE | 11.22 |
| Dividend | 2.91 (3.40%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 565 |
| Average Volume | 1,252 |
| Open | 86.70 |
| Previous Close | 87.20 |
| Day's Range | 85.50 - 86.70 |
| 52-Week Range | 65.50 - 99.50 |
| Beta | n/a |
| RSI | 56.54 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
Is This Pharmaceutical Giant a Buy After a Major Acquisition?
Merck's newest acquisition could help it launch a promising flu candidate. Several other ongoing developments are helping paint a bright post-Keytruda picture.
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?
New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.
Merck Unit Gets FDA Conditional Approval For EXZOLT CATTLE-CA1 To Treat Key Cattle Parasites
(RTTNews) - Merck Animal Health, a division of Merck & Co., Inc.(MRK), announced that the U.S. Food and Drug Administration has granted conditional approval for EXZOLT CATTLE-CA1 (fluralaner topical s...
Jim Cramer checks up on pharmaceutical company Merck
'Mad Money' host Jim Cramer takes a closer look at recent market gains out of Merck.
After Hours Most Active for Dec 4, 2025 : AVPT, NVDA, CMCSA, INTC, KO, WMB, GM, DIS, MRK, AMZN, AAPL, BSX
The NASDAQ 100 After Hours Indicator is down -2.19 to 25,579.51. The total After hours volume is currently 122,958,176 shares traded.The following are the most active stocks for the after hours sessio...
Merck & Co Inc at Citi Global Healthcare Conference Transcript
Merck & Co Inc at Citi Global Healthcare Conference Transcript
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda
Munich court halts Merck's Keytruda subcutaneous launch in Germany over Halozyme patent dispute. Read more here.
German Court Issues Injunction Against Merck's (MRK) Keytruda SC
German Court Issues Injunction Against Merck's (MRK) Keytruda SC
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc . (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline. PLRX stock is showing notable weakness. Check out ...
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
Merck (MRK) Gains FDA Conditional Approval for New Cattle Treatment
Merck (MRK) Gains FDA Conditional Approval for New Cattle Treatment
FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administr...
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Dow Movers: MRK, NVDA
In early trading on Thursday, shares of NVIDIA topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.8%. Year to date, NVIDIA registers a 36.2% gain. And t...
Guru Fundamental Report for MRK - Peter Lynch
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter...
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Dow Movers: MSFT, MRK
In early trading on Wednesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.9%. Year to date, Merck registers a 3.4% gain. And the...
DAX Up Marginally; Merck, Infineon Among Top Gainers
(RTTNews) - The German market's benchmark DAX was up in positive territory at noon on Wednesday, extending previous session's modest upmove. Data showing strong Eurozone private sector growth in Novem...
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript
Merck & Co Inc at Evercore ISI Healthcare Conference Transcript
Merck & Co Inc at Evercore ISI Healthcare Conference Transcript
Goldman Sachs Raises Merck (MRK) Price Target to $120 | MRK Stock News
Goldman Sachs Raises Merck (MRK) Price Target to $120 | MRK Stock News